Eli Lilly and Company (NYSE:LLY) Shares Sold by Phillips Financial Management LLC

Phillips Financial Management LLC trimmed its holdings in Eli Lilly and Company (NYSE:LLY) by 5.1% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,296 shares of the company’s stock after selling 69 shares during the quarter. Phillips Financial Management LLC’s holdings in Eli Lilly and Company were worth $1,149,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in the stock. PAX Financial Group LLC lifted its stake in Eli Lilly and Company by 3.4% in the first quarter. PAX Financial Group LLC now owns 458 shares of the company’s stock valued at $356,000 after buying an additional 15 shares during the last quarter. Point Break Capital Management LLC raised its position in Eli Lilly and Company by 75.9% in the 1st quarter. Point Break Capital Management LLC now owns 2,401 shares of the company’s stock valued at $1,868,000 after purchasing an additional 1,036 shares during the last quarter. Hilltop Partners LLC raised its position in Eli Lilly and Company by 7.9% in the 1st quarter. Hilltop Partners LLC now owns 975 shares of the company’s stock valued at $758,000 after purchasing an additional 71 shares during the last quarter. Capitolis Liquid Global Markets LLC acquired a new stake in Eli Lilly and Company during the 1st quarter worth $86,665,000. Finally, Atlanta Consulting Group Advisors LLC purchased a new position in Eli Lilly and Company during the 1st quarter worth $365,000. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Trading Down 5.1 %

Shares of Eli Lilly and Company stock opened at $746.20 on Monday. The company has a 50-day moving average of $882.65 and a two-hundred day moving average of $871.04. Eli Lilly and Company has a 12-month low of $561.65 and a 12-month high of $972.53. The company has a current ratio of 1.27, a quick ratio of 0.97 and a debt-to-equity ratio of 2.03. The stock has a market cap of $708.38 billion, a PE ratio of 80.67, a price-to-earnings-growth ratio of 2.82 and a beta of 0.43.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing analysts’ consensus estimates of $1.52 by ($0.34). The firm had revenue of $11.44 billion during the quarter, compared to analyst estimates of $12.09 billion. Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The business’s revenue was up 20.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.10 EPS. On average, research analysts anticipate that Eli Lilly and Company will post 13.21 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be paid a $1.30 dividend. The ex-dividend date of this dividend is Friday, November 15th. This represents a $5.20 dividend on an annualized basis and a yield of 0.70%. Eli Lilly and Company’s payout ratio is 56.22%.

Insider Buying and Selling at Eli Lilly and Company

In related news, CAO Donald A. Zakrowski sold 900 shares of the company’s stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $803.38, for a total value of $723,042.00. Following the sale, the chief accounting officer now owns 5,480 shares of the company’s stock, valued at approximately $4,402,522.40. This represents a 14.11 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.13% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on LLY shares. Bank of America decreased their target price on shares of Eli Lilly and Company from $1,150.00 to $1,100.00 and set a “buy” rating for the company in a research note on Thursday, October 31st. Wolfe Research initiated coverage on Eli Lilly and Company in a research note on Friday. They set an “outperform” rating and a $1,000.00 price objective for the company. Deutsche Bank Aktiengesellschaft lowered their target price on Eli Lilly and Company from $1,025.00 to $1,015.00 and set a “buy” rating on the stock in a research note on Monday, November 4th. Guggenheim upped their price target on Eli Lilly and Company from $884.00 to $1,030.00 and gave the stock a “buy” rating in a research note on Friday, August 16th. Finally, Redburn Atlantic upgraded shares of Eli Lilly and Company to a “hold” rating in a research report on Monday, November 4th. Four analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $1,007.94.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.